Azevan Pharmaceuticals Inc
Business Identifier: proprietary drugs for the treatment of central nervous system (CNS)
Public Profile:
Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications. Azevan Pharmaceuticals, Inc. was formerly known as Serenix Pharmaceuticals, LLC and changed its name to Azevan Pharmaceuticals, Inc. in January 2002.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
New Drugs For Stress-Related Affective Illness
Screening New Therapeutics For The Treatment Of Post Traumatic Stress Disorder
A Potential New Drug for Depression
Treating Self-Abuse In Autism And Mental Retardation